New data for investigational gene editing program presented at EHA

CRISPR Therapeutics and Vertex share new clinical data on investigational treatments for severe sickle cell disease and transfusion-dependent beta thalassemia at the European Hematology Association (EHA) Annual Meeting

Learn More

Programs

Icon Hemo 120X120

Hemoglobinopathies

Aiming to treat β-thalassemia and sickle cell disease with gene-edited hematopoietic stem cells

More


Icon Immuno 120X120

Immuno-Oncology

Creating the next generation of cell therapies for cancer enabled by gene editing

More


Icon Invivo 120X120

In Vivo

Editing cells inside the body to treat genetically-defined diseases

More


Icon Regen 120X120

Regenerative Medicine

Broadening the applications of stem cells through gene editing

More


CRISPR/Cas9

Cas9 Video Thumb

Rapidly translating a revolutionary technology into transformative therapies

Rapidly translating a revolutionary technology into transformative therapies

Join Our Team

We're looking for energetic, collaborative and talented people who like challenges, want to make a difference and have a track record of delivering results. View open opportunities

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.

Continue